EU/3/16/1815

About

On 12 January 2017, orphan designation (EU/3/16/1815) was granted by the European Commission to Adare Pharmaceuticals srl, Italy, for fluticasone propionate for the treatment of eosinophilic oesophagitis.

Key facts

Active substance
fluticasone propionate
Medicine name
-
Disease / condition
Treatment of eosinophilic oesophagitis
Date of first decision
12/01/2017
Outcome
Positive
EU designation number
EU/3/16/1815

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Adare Pharmaceuticals srl
Via Martin Luther King 13
20060 Pessano con Bornago (MI)
Italy
Tel. +39 02 95 42 83 48
E-mail: inquiriesEUROW@adarepharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating